TGFB2 and gastric cancer: We also performed KM survival analysis on the expression levels of TGFβ in multiple gastric cancer datasets, and the results showed that patients with high expression of TGFβ1 in STAD and GSE184336 had shorter survival time (Figures 2A–D), patients with high expression of TGFβ2 in STAD, GSE184336, GSE84437 and GSE62254 had shorter survival times (Figures 2E–H), and patients with high expression of TGFβ3 in GSE84437 and GSE62254 had shorter survival time (Figures 2I–L).